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Rapid tranquillisation for agitated patients in emergency
psychiatric rooms: a randomised trial of midazolam versus
haloperidol plus promethazine
TREC Collaborative Group
Abstract
Objective To compare two widely used drug
treatments for people with aggression or agitation
due to mental illness.
Design Pragmatic, randomised clinical trial.
Setting Three psychiatric emergency rooms in Rio de
Janeiro, Brazil.
Subjects 301 aggressive or agitated people.
Interventions Open treatment with intramuscular
midazolam or intramuscular haloperidol plus
promethazine.
Main outcome measures Patients tranquil or sedated
at 20 minutes. Secondary outcomes: patients tranquil
or asleep by 40, 60, and 120 minutes; restrained or
given extra drugs within 2 hours; severe adverse
events; another episode of agitation or aggression;
needing extra visits from doctor during first 24 hours;
overall antipsychotic load in first 24 hours; and not
discharged by two weeks.
Results 151 patients were randomised to midazolam,
and 150 to haloperidol-promethazine mix. Follow up
for the primary outcome was available for 298 (99%):
134/151 (89%) of patients given midazolam were
tranquil or asleep after 20 minutes compared with
101/150 (67%) of those given haloperidol plus
promethazine (relative risk 1.32 (95% confidence
interval 1.16 to 1.49)). By 40 minutes, midazolam still
had a statistically and clinically significant 13% relative
advantage (1.13 (1.01 to 1.26)). After 1 hour, about
90% of both groups were tranquil or asleep. One
important adverse event occurred in each group: a
patient given midazolam had transient respiratory
depression, and one given haloperidol-promethazine
had a grande mal seizure.
Conclusions Both treatments were effective.
Midazolam was more rapidly sedating than
haloperidol-promethazine, reducing the time people
are exposed to aggression. Adverse effects and
resources to deal with them should be considered in
the choice of the treatment.
Introduction
Health services often manage agitated or violent
people, and such behaviour is particularly prevalent in
emergency psychiatric services (10%).1 Most incidents
in psychiatric settings are secondary to severe illnesses
such as schizophrenia or substance misuse.2 Guidelines
recommend that patients should be calmed by use of
words and reassurance, a diagnostic history acquired,
and physical and laboratory tests completed before
drug treatment is started.3 However, the acute danger
of the situation often makes this impossible, with histo-
ries hurried and fragmented, diagnoses speculative,
and physical examination impossible. To ensure the
safety of everyone involved, rapid tranquillisation of
aggressive or violent patients may be unavoidable.
The drugs used in such situations should calm
patients safely and swiftly. Guidelines, however, are
usually statements of consensus and differ on which
drugs to use.3 4 Surveys of clinicians’ preferred drug
treatments also show variation,5 6 which is confirmed
by audit,7 8 although the broad class of older
generation antipsychotics and benzodiazepines are
often used.1 9 However, given the limited and
unconvincing evidence in this subject, variations in
guidance and practice are understandable. A trial of
zuclopenthixol acetate versus other typical antipsy-
chotics for treating aggressive patients with severe psy-
chiatric illness gave only equivocal results (relative risk
of “not tranquil or asleep by 1 hour” of 0.6 (95% confi-
dence interval 0.3 to 1.3)).10 Similar results were
reported for comparisons of benzodiazepines with
placebo (relative risk 0.2 (0.03 to 1.2))11 and of a
benzodiazepine-haloperidol mix with haloperidol
alone (0.67 (0.3 to 1.4)).12 There was some suggestion
of an effect, however, when haloperidol was compared
with placebo (0.2 (0.04 to 0.9))13 and benzodiazepines
were compared with typical antipsychotics (0.64 (0.4 to
0.98)).12
The TREC trial (tranquilização rápida-ensaio
clínico [rapid tranquillisation-clinical trial]) was a prag-
matic randomised trial designed for the psychiatric
emergency rooms of Rio de Janeiro. In Rio a relatively
low dose mixture of haloperidol, a typical neuroleptic,
plus promethazine, an antihistamine with sedative and
anticholinergic properties, is used for 80% of severe
psychiatric emergencies, and a benzodiazepine is a sec-
ond choice, both treatments being given intramuscu-
larly.9 14 Of the two rapidly acting benzodiazepines,
midazolam and lorazepam, only midazolam is avail-
able in Brazil as lorazepam is unstable at high
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temperatures. Haloperidol, promethazine, and mida-
zolam are on Rio’s list of essential drugs, and haloperi-
dol and promethazine are on the World Health
Organization’s model list of essential drugs.15
Most people live in low or middle income
countries, and rates of severe mental illness are consist-
ent across the world.16 As there is no evidence that psy-
chiatric emergencies are less prevalent anywhere, most
episodes of aggression for severely mentally ill people
must take place in low or middle income countries.
Although new, atypical antipsychotic drugs may
become available for use in psychiatric emergencies.
These drugs are expensive and are therefore unlikely
to affect the care of most people in need of emergency
tranquillisation in the near future.
Methods
TREC was a randomised controlled trial performed in
three public psychiatric hospitals in the city of Rio de
Janeiro, Brazil.17 These hospitals cover about 3.5
million people; half the population of the city. We
designed TREC not to interfere with the routine care
of people in the participating centres, so eligibility cri-
teria were simple and data collection limited to the
minimum.
Selection of patients
Patients were eligible for trial entry if the treating doc-
tor considered that they needed acute intramuscular
sedation because of agitation and dangerous behav-
iour and if the doctor was uncertain which treatment to
use. Patients were ineligible if the clinician believed that
one treatment represented an additional risk for the
patient.
Intervention and randomisation
We compared the standard treatment, haloperidol plus
promethazine (drawn into the same syringe), with
midazolam, both given by intramuscular injection.
Doses were at the treating doctors’ discretion.We made
flumazenil, a benzodiazepine antagonist, available at
each centre for use in the event of midazolam toxicity.
We supplied the drugs using a local pack system simi-
lar to those that had been successful in other large
studies in low and middle income countries.18
In Britain one collaborator (CEA) used Microsoft
Excel to generate even random numbers less than 10.
These block sizes were then applied to a table of
random numbers. To help ensure concealment of allo-
cation, CEA produced a table of allocation sequence
independent of block size. He sent these tables to a
Brazilian colleague independent of the TREC team,
who ensured that the correct drug was in the consecu-
tively numbered local pack before it was sealed. These
packs were constructed of cardboard, were identical,
and were sealed firmly with tape, across which the con-
secutive number was written. They contained either
one ampoule of midazolam 15 mg or two ampoules of
haloperidol 5 mg plus one of promethazine 50 mg,
along with a syringe, needle, swabs, and a follow up
form. Verification of order of allocated treatment was
monitored throughout the study.17 If a patient met the
eligibility criteria, the treating clinician took the next
consecutive box.
Outcomes
Part of an earlier survey of psychiatric emergency
room practice in Rio was to ask nursing and medical
staff for their outcome of primary interest for
emergency tranquillisation.9 The staff chose “tranquil-
lised or asleep by 20 minutes.” Patients were considered
tranquillised when they were calm and peaceful—that
is, neither agitated nor restless, and not showing
threatening verbal behaviour or physical aggression
against objects, other people, or themselves.
Secondary outcomes were patients asleep by 20
minutes; tranquil or asleep by 40, 60, and 120 minutes;
physically restrained or given additional drugs within
two hours; severe adverse events; having another
episode of agitation or aggression; needing extra visits
from the treating doctor during the subsequent 24
hours; overall antipsychotic load in the first 24 hours;
and still in hospital after two weeks. As this study was
designed not to burden routine practice, we were
restricted to the information reliably recorded in
medical notes, such as those adverse effects considered
dangerous.
Procedures
Before opening a TREC box, and while still blind to the
allocated treatment, a participating doctor completed
the form printed on its top. This constituted trial entry.
This form recorded the doctor’s estimate of the sever-
ity and cause of the episode of agitation or
aggression.17 The box was then opened, the treatment
given, and a timer was set to ring every 20 minutes for
the first hour.When the timer rang the attending nurse
assessed the outcomes. Other data were extracted from
the patient’s notes.
The accuracy of assessment of primary outcome
was checked by other raters, nurses or doctors not
involved in the management of the emergency. Blind
to the allocated treatment, and unknown to the
clinicians looking after the patient, they timed the
period between injection and tranquillisation or sleep
for 10% of patients.
Sample size
In such a stressful situation, even a small advantage for
an intervention could represent a worthwhile benefit.
Every additional minute of aggression exposes
everyone to danger. We aimed to detect difference in
the proportion of patients tranquillised by 20 minutes:
to detect a difference between groups of at least 20% at
5% level of significance ( error) and 80% probability
(1 −  error), we needed 300 patients.
Statistical analysis
We assessed randomisation by comparing (without use
of statistical tests) sociodemographic and clinical char-
acteristics between the two treatment groups and
calculated relative risks and number needed to treat
(with 95% confidence intervals) for primary and
secondary outcomes using intention to treat analysis.
We calculated and interpreted confidence intervals for
numbers needed to treat according to Altman.19 We
evaluated statistical significance at the 5% level for the
primary outcome and at 1% for secondary outcomes.
We used  statistics for estimating inter-rater agree-
ment for the primary outcome. We entered data in
Epi-Info 6.04 and analysed them with SPSS 9.0.
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Ethical issues
Most eligible patients are brought to the emergency
rooms by the police without relatives and are not able
to give consent for participation. Trials without
patients’ consent are considered justifiable on two con-
ditions: firstly, no other context exists in which to
answer the question, and, secondly, all trial patients get
clear therapeutic benefit from whichever treatment
arm they are allocated to.20–22 If relatives were present,
they were fully informed and their consent requested.
We compared standard care in Rio (haloperidol plus
promethazine) with midazolam, a drug used routinely
for tranquillisation elsewhere and available to every
public hospital in Rio. Our protocol was approved by
the Brazilian Council of Ethics in Research, the ethics
committees of all the institutions involved, and a local
group representing the relatives of mentally ill people.
Results
Between June and December 2001, 301 patients were
randomised to treatment, 95% between 8 am and mid-
night, and 16% at the weekend. The principal
investigator (GH) estimated the numbers of eligible
people not randomised during that period through
observation of 80 aggressive episodes. Two of the 80
people were ineligible, and 20 of the remainder could
not be included as no beds were available in participat-
ing centres. The rest were randomised. For the primary
outcome, data were available for 298 (99%) people (see
figure).
Patients in the two treatment groups had similar
baseline characteristics and estimated severity of agita-
tion (table 1), suggesting that randomisation was
successful. The experienced staff estimated most
patients to be markedly disturbed as a result of psycho-
sis (table 1). The patients’ demographic and diagnostic
characteristics were as expected from the characteris-
tics of the client population who receive emergency
psychiatric intervention in the three hospitals in Rio de
Janeiro.
The time from injection to tranquillisation or sleep
was checked by independent observers for 24 (8%) of
the patients. For 22 of these patients there was full
agreement. The two discrepancies resulted from an
observer’s estimate being 10 minutes greater than that
of the attending nurse, and from a tranquillised patient
being roused to become aggressive again by another
patient (estimated overall = 0.83 after adjustment for
prevalence).
Of the 148 patients given haloperidol-
promethazine mix, 77 were given 5 mg of haloperidol
and 71 were given 10 mg, while 147 were given 50 mg
of promethazine and one was given 25 mg. Of the 150
patients given midazolam, 124 were given 15 mg and
26 were given 7.5 mg.
Outcomes
Table 2 shows the outcomes for the two treatments. By
20 minutes after injection, 32% more of the patients
given midazolam were tranquil or asleep compared
with those given haloperidol-promethazine (number
needed to treat for one extra patient to be
tranquillised = 5 (95% confidence interval 3 to 8)). By
40 minutes, although most patients were tranquil or
asleep, midazolam still had a statistically and clinically
significant 13% relative advantage. By an hour, about
90% of both groups were tranquil or asleep.
Twice as many of the patients given midazolam
were asleep by 20 minutes as were those given
haloperidol-promethazine. This difference remained
statistically and clinically significant up to two hours
after injection. Midazolam rapidly sedated patients
and kept most sedated for up to two hours. The
haloperidol-promethazine mix tranquillised and
sedated patients, but with a slower onset of action. A
post hoc analysis of response according to diagnosis
(psychosis or substance misuse) and severity of
disturbance found no differences (data not shown).
Two severe adverse events were reported, one in
each group and both within the first 20 minutes after
drug administration. One aggressive woman who had
epilepsy was given haloperidol (5 mg) plus prometh-
azine (50 mg) and had a grande mal seizure 15
minutes after injection. With benzodiazepines, she
settled and recovered swiftly. A man with alcohol
Assessed for eligibility (n=416)*
Randomised (n=301)
Excluded (n=115)*
  Not meeting inclusion criteria (n=12)*
  Due to bed shortages (n=103)*
Allocated to haloperidol-promethazine (n=150)
  Received intervention (n=148)
  Did not receive intervention (n=2)
    (1. After TREC box was opened family
    withdrew consent. 2. Patient ran away
    before receiving injection)
Allocated to midazolam (n=151)
  Received intervention (n=150)
  Did not receive intervention (n=1)
    (After TREC box was opened family
    withdrew consent for patient to be in
    hospital)
Lost to follow up:
  For primary outcome (n=0)
  For 24 hour outcomes (n=0)
    (Incomplete data for maximum of 7 patients.
    Information not found in notes)
  For 14 days outcomes (n=3)
    (Transfer to another hospital, notes lost)
Lost to follow up:
  For primary outcome (n=0)
  For 24 hour outcomes (n=0)
    (Incomplete data for maximum of 7 patients.
    Information not found in notes)
  For 14 days outcomes (n=0)
Analysed for primary outcome (n=150)
Excluded from analysis (n=0)
  (Two people who did not receive intervention
  were assumed not to be tranquil for first
  2 hours)
Analysed for primary outcome (n=151)
Excluded from analysis (n=0)
  (One person who did not receive intervention
  was assumed not to be tranquil for first
  2 hours)
* Figures are estimates from observation of subsample
Flow of patients through various stages of TREC study
Table 1 Baseline demographic and clinical characteristics of 301 patients given
midazolam or haloperidol-promethazine mix for emergency intramuscular sedation
because of agitation and dangerous behaviour. Values are number (percentage) of
patients unless stated otherwise
Midazolam (n=151)
Haloperidol-promethazine
(n=150)
Men 72 (48) 74 (49)
First psychiatric attendance 14 (9) 12 (8)
Severity of agitation:
Moderately 52 (34) 56 (37)
Markedly 99 (66) 93 (62)
Presumed cause:
Psychosis 107 (71) 112 (75)
Substance misuse 30 (20) 21 (14)
Other 14 (9) 16 (11)
Mean (SD) age (years) 38 (11) 38 (12)
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induced, and perhaps also cocaine induced, aggres-
sion was given midazolam (15 mg). His respiratory
rate fell immediately, and he became cyanotic; by 15
minutes his respiratory rate was 32 breaths/minute.
He recovered fully after being given flumazenil 0.25
mg intravenously.
Additional tranquillising drugs were rarely needed
in the first two hours, and no difference between the
groups was apparent. Restraints were used for 73
people, with no statistically significant difference
between the groups, though the fact that 5% fewer
people in the midazolam group needed restraints by
two hours may be considered clinically significant.
During the first 24 hours, 74 people had another
significant episode of aggression. Although there was
no statistically significant difference between the two
treatments, 6% more of the patients given midazolam
experienced a second episode of aggression.
Most of the patients accepted oral medication, and
giving a benzodiazepine did not seem to affect patients’
total load of antipsychotic drugs in the first 24 hours.
The mean doses in chlorpromazine equivalents during
the first 24 hours were 368 mg (SD 283, median 333)
for the midazolam group, and 355 mg (SD 267,
median 333) for the haloperidol-promethazine group
(two sided permutation test P = 0.67).
After two weeks, 73 (48%) of the patients who had
been given midazolam were discharged, compared
with 69 (46%) of those given haloperidol-
promethazine (relative risk 1.05 (0.77 to 1.44)).
Discussion
This study evaluated the effect of two widely available
and inexpensive drug treatments for emergency
tranquillisation of aggressive or agitated patients with
mental illness. Relatively low doses of both treatments
were rapidly effective. However, about a third more
people given midazolam were tranquil or asleep by 20
minutes compared with those given haloperidol-
promethazine. One in five people remained disturbed
for 40-60 minutes longer if given haloperidol-
promethazine rather than midazolam. Tranquillisation
to sleep was more common with midazolam than with
haloperidol-promethazine. Use of the benzodiazepine
had no apparent consequences for long term care.
Both drug regimens seemed reasonably safe. A sei-
zure occurred in a person with epilepsy, and
respiratory depression occurred in someone whose
risk had been increased by substance misuse. Fits and
respiratory depression were easily reversed with no
repercussions. The results of this study are applicable
to general emergency rooms and inpatients in psychi-
atric and other settings, but the resources available for
managing adverse effects should be considered.
Few of the patients required additional drugs in the
first two hours after treatment, but a fifth of patients
were restrained during this period. In Rio de Janeiro it
is more common to put patients who are still not tran-
quillised in restraints rather than giving them more
drugs.9
Table 2 Outcomes for 301 patients given emergency intramuscular sedation with midazolam or haloperidol-promethazine mix because
of agitation and dangerous behaviour. Values are number (percentage) of patients unless stated otherwise
Patient outcomes Midazolam (n=151)
Haloperidol-promethazine
(n=150) Relative risk (CI)* Difference in % risk (CI)*
By 20 minutes after injection
Tranquil or asleep 134 (89) 101 (67) 1.32 (1.16 to 1.49) 22 (12 to 30)
Asleep 93 (62) 43 (29) 2.15 (1.48 to 3.11) 33 (19 to 47)
Serious adverse effect 1 (1) 1 (1)
Unknown 1 (1) 2 (1)
By 40 minutes after injection
Tranquil or asleep 141 (93) 124 (83) 1.13 (1.01 to 1.26) 10 (1 to 20)
Asleep 118 (78) 69 (46) 1.70 (1.32 to 2.19) 32 (18 to 46)
Unknown 1 (1) 2 (1)
By 60 minutes after injection
Tranquil or asleep 141 (93) 131 (87) 1.07 (0.97 to 1.18) 6 (−3 to 15)
Asleep 120 (79) 83 (55) 1.44 (1.16 to 1.78) 24 (11 to 38)
Unknown 1 (1) 2 (1)
By 120 minutes after injection
Tranquil or asleep 144 (95) 138 (92) 1.04 (0.96 to 1.12) 3 (−4 to 11)
Asleep 125 (83) 95 (63) 1.31 (1.08 to 1.57) 20 (7 to 32)
No additional tranquillising drugs 149 (99) 143 (95) 1.04 (0.98 to 1.09) 4 (−2 to 8)
Not needing restraints 118 (78) 110 (73) 1.07 (0.90 to 1.26) 5 (−8 to 18)
Unknown 1 (1) 2 (1)
By 24 hours after injection
No other episode of aggression: 107 (71) 111 (74) 0.96 (0.80 to 1.15) −3 (−16 to 10)
Unknown 2 (1) 7 (5)
Doctor not called to see patient: 100 (66) 107 (71) 0.93 (0.76 to 1.13) −5 (−19 to 8)
Unknown 2 (1) 4 (3)
Accepting oral medication: 135 (89) 139 (93) 0.96 (0.88 to 1.06) −4 (−12 to 5)
Unknown 7 (5) 5 (3)
By 2 weeks after injection
Discharged 73 (48) 69 (46) 1.05 (0.77 to 1.44) 2 (−12 to 17)
Unknown 0 3 (2)
*99% confidence intervals, except for primary outcome (tranquil or asleep by 20 minutes), which is 95%.
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Strengths and limitations of study
Trials evaluating the management of aggressive or
violent people are rare and usually small.11–14 23 24 TREC
is large in comparison, with a completeness of data col-
lection not seen even in short duration randomised
trials for psychoses. This study took place in a middle
income country, because of the commitment of
clinicians, institutions, ethics committees, and consumer
groups to base local practice on good evidence. The
pragmatic design, rare in mental health trials, simplified
rather than complicated everyday practice. This strategy
increased the chance of selecting a sample of patients
representative of those who usually attend the emer-
gency rooms. This study provides a reference for those
evaluating new drugs for psychiatric emergencies.
This study evaluated the open giving of the two
treatments. Blinding of outcome was never envisaged,
and the experienced healthcare professionals who
participated could accurately tell if and when a person
was asleep or tranquil.
Conclusions
Both treatments worked, but midazolam was clearly
more effective than haloperidol-promethazine in
terms of rapid sedation. Serious adverse effects for
both treatments were rare. Even in the chaos of a busy
psychiatric emergency room, these adverse effects
should never threaten life. Health professionals might
prefer to use midazolam in circumstances where rapid
sedation is necessary and after which good observation
is possible. Where good observation is impossible, or
rapid sedation not paramount, the haloperidol-
promethazine mix might be preferred. Consistent
clinical practice in Brazil9 is now supported with
evidence, and other countries that use the haloperidol-
promethazine mix (such as India) or midazolam (such
as Australia and Thailand) can also be more informed.
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